Generate $300 in Annual Dividend Income With a $2,670 Portfolio? Here's How Three High-Yield Stocks Stack Up

Why Safe, High-Yield Dividend Stocks Are Worth Your Attention

Over five decades of market data tells a compelling story: companies that consistently pay dividends don’t just deliver superior returns—they do it with less turbulence than the broader market. Research covering 1973 through 2024 reveals that dividend-paying equities have nearly doubled the annual returns of non-payers (9.2% versus 4.31%), while simultaneously experiencing lower volatility than the S&P 500 benchmark. This historical pattern has made dividend investing a cornerstone strategy for building reliable income streams.

The challenge, however, lies in finding truly durable high-yield opportunities. While the market offers plenty of ultra-high-yield stocks—those trading at four times or more than the S&P 500’s yield—not all of them merit investor attention. Thorough due diligence is essential to separate genuine income opportunities from value traps.

The Three-Pronged Approach: Targeting $300 Annual Income

To achieve $300 in dividend income annually, an investor would allocate approximately $2,670 across three carefully selected high-yield stocks, each contributing roughly equal portions. Here are three candidates currently offering yields between 6.9% and 13.6%:

AGNC Investment: Mortgage REIT With 13.28% Yield

Mortgage real estate investment trusts occupy a unique market niche, and AGNC Investment (NASDAQ: AGNC) exemplifies why they appeal to income seekers. Trading at a 13.3% yield as of late December, this mortgage REIT distributes payments monthly—a feature that appeals to those seeking regular cash flow.

The mechanics underlying mortgage REITs involve borrowing at shorter-term rates to purchase higher-yielding assets like mortgage-backed securities. This strategy creates sensitivity to Federal Reserve policy decisions. When the central bank enters rate-cutting cycles, AGNC’s borrowing costs typically decline, allowing the company to expand its net interest margin (the spread between asset yields and borrowing costs).

The composition of AGNC’s nearly $91 billion portfolio underscores its income sustainability. As of September 30, approximately $90.1 billion resided in agency mortgage-backed securities and to-be-announced securities backed by federal guarantee, with just $0.7 billion exposed to credit risk. This conservative positioning, while moderating yield potential compared to riskier alternatives, permits AGNC to employ leverage effectively and maintain its premium income stream.

Pfizer: Pharmaceutical Giant Offering 6.87% Yield

Pfizer (NYSE: PFE) has become an overlooked dividend opportunity, trading near 13-year lows despite fundamental improvements in its business trajectory. The stock’s decline stems largely from investor disappointment over peak COVID-19 therapy revenues, which exceeded $56 billion in 2022 before declining sharply.

This narrative misses the bigger picture. Between 2020 and 2025, Pfizer expanded its full-year revenue from $41.9 billion to a guided $62 billion—a 48% increase over five years. Beyond COVID-related sales, the company’s core business has strengthened meaningfully. Its December 2023 acquisition of oncology specialist Seagen continues yielding results: the oncology segment achieved 7% operating growth through the first nine months of 2025, reflecting expanding demand for cancer therapeutics.

Cost synergies further enhance the investment case. Management projects $7.2 billion in net cost savings by end-2026, improvements that should lift operating margins and valuation multiples. With a forward price-to-earnings ratio hovering near 8, Pfizer appears cheaply valued relative to its growth and margin expansion potential—making its nearly 7% yield particularly attractive.

PennantPark Floating Rate Capital: Business Development Company at 13.61% Yield

PennantPark Floating Rate Capital (NYSE: PFLT), a business development company, rounds out the trio with a 13.6% monthly dividend yield. BDCs invest in equity and debt securities of mid-market companies lacking traditional banking access, generating above-average yields from their lending activities.

PennantPark’s $2.77 billion portfolio consists predominantly of debt securities, with over 99% comprising variable-rate loans. This floating-rate characteristic creates a dual dynamic: while an easing monetary environment would compress yields, the Federal Reserve’s measured approach to rate cuts has allowed PennantPark to maintain double-digit yields. As of fiscal year-end September 30, 2025, the portfolio generated a weighted-average yield on debt investments of 10.2%.

Portfolio quality remains strong: diversification across an average investment size of just $16.9 million, combined with 99%+ allocation to first-lien secured debt (which ranks first for repayment in default scenarios), provides meaningful downside protection. With PFLT trading at a discount to its book value, the entry point appears advantageous for income-focused investors.

The Bottom Line on High-Yield Stocks

Constructing a $2,670 portfolio split equally among AGNC, Pfizer, and PennantPark positions investors to capture roughly $300 in annual dividend income while maintaining exposure to different yield drivers: mortgage credit, pharmaceutical fundamentals, and middle-market lending. Each security offers distinct risk-return characteristics, requiring individual evaluation before investment.